Since GATA3 is associated with a more epithelial and luminal subtype, an increased understanding of the mechanisms utilized by GATA3 to reverse EMT and TGFß response and to promote a more luminal subtype may also lead to the identification of novel approaches to sensitize resistant breast cancers to therapies. The gene discussed is GATA3; the disease is breast carcinoma.